跳至主要内容
临床试验/NCT05378516
NCT05378516Unknown不适用

Placental Pathology and Inflammatory Factor Analysis of Obstetric Antiphospholipid Syndrome Patients

Peking University People's Hospital1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2022年1月1日最近更新:
适应症

试验速览

阶段
不适用
入组人数
40
试验地点
1
主要终点
expression of ACC1 in placenta in pregnancy with/without antiphospholipid syndrome

研究概览

简要总结

This investigation is on placental pathological changes and inflammatory factors associated with obstetric antiphospholipid syndrome.

详细描述

  1. To clarify the correlation between antiphospholipid antibody, ACC1 expression level, Treg cell and placental pathological changes associated with antiphospholipid syndrome. 2. Reveal that antiphospholipid antibodies affect Treg cell differentiation through the key enzyme of lipid metabolism ACC1.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • pregnant women with antiphospholipid syndrome (diagnosed by experts with clinical evidence) and healthy pregnant women without antiphospholipid syndrome as a control group
  • consent to join this study and finish the informed consents

排除标准

  • pregnant women with other autoimmune diseases

结局指标

主要结局

expression of ACC1 in placenta in pregnancy with/without antiphospholipid syndrome

时间窗: in two years

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Yang Jingjing

Deputy chief physician

Peking University People's Hospital

研究点 (1)

Loading locations...

相似试验